Clinical Trial Update: An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating tocilizumab (RoActemra/Actemra) in adults with moderate to severe rheumatoid arthritis; results were posted after completion…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• RoActemra/Actemra (tocilizumab) (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-09-21